InvestorsHub Logo
Followers 60
Posts 7434
Boards Moderated 0
Alias Born 10/20/2014

Re: Jasbg post# 338907

Friday, 05/07/2021 7:06:09 AM

Friday, May 07, 2021 7:06:09 AM

Post# of 428972
Jasbg, AMRN management botched the launch of Vascepa in the US. Whatever
benefits Vascepa may have (and I believe it has a myriad of benefits
beyond CVD,) they will not do anything with it, unless or until it is
placed in the right BP hands!

Thero and his great management team took a great drug and lid it to waste.
There is enough known about Vascepa's mode of action and how it would
be a candidate to treat the inflammatory affects of Covid-19, yet
nothing is said about Vascepa by the US (or other) government medical
authorities. Dr. Scott Gottlieb, on the BOD of Pfizer and former FDA
commissioner is on CNBC every day and he will always talk about Vaccines
but will never talk about Vascepa...ever!

BP knows how to get things to happen that are positive for the interests
they serve. Amarin does not! Given all of the news around Covid...has
there ever been one news article that speculated about the value that
Vascepa might have as a Covid-19 treatment? Nope, none! Zero!
Maybe BP has no interest in AMRN and Vascepa...or maybe AMRN
management is incapable of generating such inyerest because the BOD
of AMRN and Thero are just lame and pathetic.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News